Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

The "Rapid Acting Insulin Market Report, Forecast by Product, Indication, Distribution Channel, Countries and Company ...

The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11.17 billion by 2032, from US$ 7.36 billion in 2023. The market is mainly driven by growth rate of diabetes ...

Arecor Presents Positive Data From Phase I Clinical Trial Of Ultra-Concentrated Ultra-Rapid Acting Insulin At278 In ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024 -Pre-clinical ...

Type 2 diabetes is characterized by the body's inability to use insulin effectively. Insulin is a hormone that helps regulate metabolism properly. The condition is the most common type of ...

Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024-Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for peopl ...

Insulin Aspart + Insulin Aspart Protamine is a combination of two medicines used to improve blood sugar control in people with type 1 and type 2 diabetes mellitus. It is a fast-acting type of insulin ...